Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of Oxabact in primary hyperoxaluria
NL-OMON47491Phase 3Completed
- Sponsor
- OxThera AB
- Start
- Jan 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary hyperoxaluria (PH) comparing Oxabact with Placebo (2 arms). Primary endpoint: Change from baseline in total plasma oxalate concentration after 52 weeks. Started Jan 2018; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NL-OMON47491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47491.